CX-4945/CX4945

溶解度:DMSO

储存条件:-20°C for 2 years

生物活性

CX-4945 is a first-in-class, orally active, potent and selective inhibitor of the protein kinase CK2. It is currently in human clinical trials as a potential treatment for various cancers.

CX-4945 is a novel, orally administered small molecule designed to
potently and selectively inhibit protein kinase CK2, a previously unexploited molecular
target with well documented roles in many cancers. In vitro, CX-4945 selectively kills
cancer cells by modulating key survival pathways, resulting in inhibition of proliferation,
promotion of apoptosis and cell cycle arrest. Pre-clinically, CX-4945 has demonstrated
single-agent potency in suppressing xenograft tumor growth with a wide therapeutic
window. The objectives of this phase I study are to determine the maximum tolerated
dose (MTD) and dose limiting toxicities (DLTs), to characterize the pharmacokinetics
(PKs), and to study the pharmacodynamic effects of CX-4945.

参考文献

1.Phase I Clinical Trial of CX-4945: A First-in-Class, Orally Administered